These sections comprise more than a third of the book, representing the weight of these issues at the Forum. In the two overviews that introduce these sections, the editors analyze the information from the researcher's point of view and point out the advances in these areas. The chapter on genetic testing of high-risk women for BRCA1 and BRCA2 has practical implications, and the chapter on endometriosis and its relationship with ovarian cancer provides interesting studies from the genetic point of view. The four chapters in Section 3 focus on the analytic approaches to the diagnosis and management of ovarian cancer. After an interesting overview of the progress in screening for ovarian cancer, other topics discussed include the quantification of the risk of ovarian cancer with use of longitudinal CA125 levels, prognostic factors, and the cost-effectiveness of screening strategies.
Experimental therapeutics is the overall focus of the next three parts of the book.
Section 5 consists of papers on the methodology for dose intensification and includes a discussion of strategies to overcome chemotherapy resistance, an exhaustive review of the current studies on high-dose chemotherapy, and findings on intraperitonal therapy. The topic of Section 6 is new treatment strategies in ovarian cancer, including new drugs and their combination. Section 7 focuses on the quality of life and ethical issues associated with ovarian cancer. Conclusions and recommendations comprise the last section of the book, with contributions from researchers and clinical practitioners on the highlights from the four-day symposium.